Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1876 entries
Sorted by: Best Match Show Resources per page
World economy: how much can we afford to spend on medical research?.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Arsenis GD.
PMID: 3148336
Biomed Pharmacother. 1988;42(10):635-8.

No abstract available.

Cite
Arsenis GD. World economy: how much can we afford to spend on medical research?. Biomed Pharmacother. 1988;42(10):635-8
Arsenis, G. D. (1988). World economy: how much can we afford to spend on medical research?. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 42(10), 635-8.
Arsenis, G D. "World economy: how much can we afford to spend on medical research?." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 42,10 (1988): 635-8.
Arsenis GD. World economy: how much can we afford to spend on medical research?. Biomed Pharmacother. 1988;42(10):635-8. PMID: 3148336.
Copy Download .nbib Format: NLM
WITHDRAWN: Sodium butyrate protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Hu X, Xu C, Zhou X, He B, Wu L, Cui B, Lu Z, Jiang H.
PMID: 20950992
Biomed Pharmacother. 2010 Sep 25; doi: 10.1016/j.biopha.2010.09.005. Epub 2010 Sep 25.

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

Cite
Hu X, Xu C, Zhou X, et al. WITHDRAWN: Sodium butyrate protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Biomed Pharmacother. 2010;doi: 10.1016/j.biopha.2010.09.005.
Hu, X., Xu, C., Zhou, X., He, B., Wu, L., Cui, B., Lu, Z., & Jiang, H. (2010). WITHDRAWN: Sodium butyrate protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, . https://doi.org/10.1016/j.biopha.2010.09.005
Hu, Xiaorong, et al. "WITHDRAWN: Sodium butyrate protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. (2010). doi: https://doi.org/10.1016/j.biopha.2010.09.005
Hu X, Xu C, Zhou X, He B, Wu L, Cui B, Lu Z, Jiang H. WITHDRAWN: Sodium butyrate protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Biomed Pharmacother. 2010 Sep 25; doi: 10.1016/j.biopha.2010.09.005. Epub 2010 Sep 25. PMID: 20950992.
Copy Download .nbib Format: NLM
WITHDRAWN: Altered oxidative stress indexes related to disease progression marker in human immunodeficiency virus infected patients with antiretroviral therapy.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Gil L, Tarinas A, Hernández D, Riverón BV, Pérez D, Tápanes R, Capo V, Pérez J.
PMID: 20951539
Biomed Pharmacother. 2010 Sep 25; doi: 10.1016/j.biopha.2010.09.009. Epub 2010 Sep 25.

The Publisher regrets that this article is an accidental duplication of an article that has already been published, http://dx.doi.org/10.1016/j.biomag.2010.09.001. The duplicate article has therefore been withdrawn.

Cite
Gil L, Tarinas A, Hernández D, et al. WITHDRAWN: Altered oxidative stress indexes related to disease progression marker in human immunodeficiency virus infected patients with antiretroviral therapy. Biomed Pharmacother. 2010;doi: 10.1016/j.biopha.2010.09.009.
Gil, L., Tarinas, A., Hernández, D., Riverón, B. V., Pérez, D., Tápanes, R., Capo, V., & Pérez, J. (2010). WITHDRAWN: Altered oxidative stress indexes related to disease progression marker in human immunodeficiency virus infected patients with antiretroviral therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, . https://doi.org/10.1016/j.biopha.2010.09.009
Gil, Lizette, et al. "WITHDRAWN: Altered oxidative stress indexes related to disease progression marker in human immunodeficiency virus infected patients with antiretroviral therapy." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. (2010). doi: https://doi.org/10.1016/j.biopha.2010.09.009
Gil L, Tarinas A, Hernández D, Riverón BV, Pérez D, Tápanes R, Capo V, Pérez J. WITHDRAWN: Altered oxidative stress indexes related to disease progression marker in human immunodeficiency virus infected patients with antiretroviral therapy. Biomed Pharmacother. 2010 Sep 25; doi: 10.1016/j.biopha.2010.09.009. Epub 2010 Sep 25. PMID: 20951539.
Copy Download .nbib Format: NLM
WITHDRAWN: Propofol reduces MMPs expression by inhibiting PI3K/AKT activity in human HepG2 cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Zhou QL, Yang CX, Liang H, Liu HZ, Wang HB, Liu Y, Lai XH, Gu MN.
PMID: 23582789
Biomed Pharmacother. 2013 Feb 14; doi: 10.1016/j.biopha.2013.01.005. Epub 2013 Feb 14.

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

Cite
Zhou QL, Yang CX, Liang H, et al. WITHDRAWN: Propofol reduces MMPs expression by inhibiting PI3K/AKT activity in human HepG2 cells. Biomed Pharmacother. 2013;doi: 10.1016/j.biopha.2013.01.005.
Zhou, Q. L., Yang, C. X., Liang, H., Liu, H. Z., Wang, H. B., Liu, Y., Lai, X. H., & Gu, M. N. (2013). WITHDRAWN: Propofol reduces MMPs expression by inhibiting PI3K/AKT activity in human HepG2 cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, . https://doi.org/10.1016/j.biopha.2013.01.005
Zhou, Qiao-Ling, et al. "WITHDRAWN: Propofol reduces MMPs expression by inhibiting PI3K/AKT activity in human HepG2 cells." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. (2013). doi: https://doi.org/10.1016/j.biopha.2013.01.005
Zhou QL, Yang CX, Liang H, Liu HZ, Wang HB, Liu Y, Lai XH, Gu MN. WITHDRAWN: Propofol reduces MMPs expression by inhibiting PI3K/AKT activity in human HepG2 cells. Biomed Pharmacother. 2013 Feb 14; doi: 10.1016/j.biopha.2013.01.005. Epub 2013 Feb 14. PMID: 23582789.
Copy Download .nbib Format: NLM
IMS health annual data show expanding pharmaceutical market growth--three-way tie for number one in global pharmaceutical sales.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

[No authors listed]
PMID: 10424254
Biomed Pharmacother. 1999 Jun;53(5):290-2.

No abstract available.

Cite
IMS health annual data show expanding pharmaceutical market growth--three-way tie for number one in global pharmaceutical sales. Biomed Pharmacother. 1999;53(5):290-2
(1999). IMS health annual data show expanding pharmaceutical market growth--three-way tie for number one in global pharmaceutical sales. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 53(5), 290-2.
"IMS health annual data show expanding pharmaceutical market growth--three-way tie for number one in global pharmaceutical sales." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 53,5 (1999): 290-2.
IMS health annual data show expanding pharmaceutical market growth--three-way tie for number one in global pharmaceutical sales. Biomed Pharmacother. 1999 Jun;53(5):290-2. PMID: 10424254.
Copy Download .nbib Format: NLM
Corrigendum to "double sword role of EZH2 in leukemia" [Biomed. Pharmacother. 98 (2018) 626-635].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Safaei S, Baradaran B, Hagh MF, Alivand MR, Talebi M, Gharibi T, Solali S.
PMID: 29525673
Biomed Pharmacother. 2018 May;101:786. doi: 10.1016/j.biopha.2018.02.101. Epub 2018 Mar 22.

No abstract available.

Cite
Safaei S, Baradaran B, Hagh MF, et al. Corrigendum to "double sword role of EZH2 in leukemia" [Biomed. Pharmacother. 98 (2018) 626-635]. Biomed Pharmacother. 2018;101:786doi: 10.1016/j.biopha.2018.02.101.
Safaei, S., Baradaran, B., Hagh, M. F., Alivand, M. R., Talebi, M., Gharibi, T., & Solali, S. (2018). Corrigendum to "double sword role of EZH2 in leukemia" [Biomed. Pharmacother. 98 (2018) 626-635]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 101786. https://doi.org/10.1016/j.biopha.2018.02.101
Safaei, Sahar, et al. "Corrigendum to "double sword role of EZH2 in leukemia" [Biomed. Pharmacother. 98 (2018) 626-635]." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 101 (2018): 786. doi: https://doi.org/10.1016/j.biopha.2018.02.101
Safaei S, Baradaran B, Hagh MF, Alivand MR, Talebi M, Gharibi T, Solali S. Corrigendum to "double sword role of EZH2 in leukemia" [Biomed. Pharmacother. 98 (2018) 626-635]. Biomed Pharmacother. 2018 May;101:786. doi: 10.1016/j.biopha.2018.02.101. Epub 2018 Mar 22. PMID: 29525673.
Copy Download .nbib Format: NLM
Corrigendum to "Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice" [Biomed. Pharmacother. 118 (2019) 109206].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Hou Q, Zhu S, Zhang C, Huang Y, Guo Y, Li P, Chen X, Wen Y, Han Q, Liu F.
PMID: 31471002
Biomed Pharmacother. 2019 Oct;118:109290. doi: 10.1016/j.biopha.2019.109290. Epub 2019 Aug 27.

No abstract available.

Cite
Hou Q, Zhu S, Zhang C, et al. Corrigendum to "Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice" [Biomed. Pharmacother. 118 (2019) 109206]. Biomed Pharmacother. 2019;118:109290doi: 10.1016/j.biopha.2019.109290.
Hou, Q., Zhu, S., Zhang, C., Huang, Y., Guo, Y., Li, P., Chen, X., Wen, Y., Han, Q., & Liu, F. (2019). Corrigendum to "Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice" [Biomed. Pharmacother. 118 (2019) 109206]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 118109290. https://doi.org/10.1016/j.biopha.2019.109290
Hou, Qiuke, et al. "Corrigendum to "Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice" [Biomed. Pharmacother. 118 (2019) 109206]." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 118 (2019): 109290. doi: https://doi.org/10.1016/j.biopha.2019.109290
Hou Q, Zhu S, Zhang C, Huang Y, Guo Y, Li P, Chen X, Wen Y, Han Q, Liu F. Corrigendum to "Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice" [Biomed. Pharmacother. 118 (2019) 109206]. Biomed Pharmacother. 2019 Oct;118:109290. doi: 10.1016/j.biopha.2019.109290. Epub 2019 Aug 27. PMID: 31471002.
Copy Download .nbib Format: NLM
Long non-coding RNAs (lncRNAs) and viral infections.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Zhang Q, Jeang KT.
PMID: 23645970
Biomed Pharmacother. 2013 Mar 01;3(1):34-42. doi: 10.1016/j.biomed.2013.01.001.

In this review, we focus on the roles of lncRNAs, including cellular and viral lncRNAs, in virus replication in infected cells. We survey the interactions and functions of several cellular lncRNAs such as

Cite
Zhang Q, Jeang KT. Long non-coding RNAs (lncRNAs) and viral infections. Biomed Pharmacother. 2013;3(1):34-42doi: 10.1016/j.biomed.2013.01.001.
Zhang, Q., & Jeang, K. T. (2013). Long non-coding RNAs (lncRNAs) and viral infections. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 3(1), 34-42. https://doi.org/10.1016/j.biomed.2013.01.001
Zhang, Quan, and Jeang, Kuan-Teh. "Long non-coding RNAs (lncRNAs) and viral infections." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 3,1 (2013): 34-42. doi: https://doi.org/10.1016/j.biomed.2013.01.001
Zhang Q, Jeang KT. Long non-coding RNAs (lncRNAs) and viral infections. Biomed Pharmacother. 2013 Mar 01;3(1):34-42. doi: 10.1016/j.biomed.2013.01.001. PMID: 23645970; PMCID: PMC3641704.
Copy Download .nbib Format: NLM
Corrigendum to "Luteolin, a flavonoid, as an anticancer agent: A review" [Biomed. Pharmacother. 112 (2019) 108612].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Imran M, Rauf A, Abu-Izneid T, Nadeem M, Shariati MA, Khan IA, Imran A, Erdogan Orhan I, Rizwan M, Atif M, Aslam Gondal T, Mubarak MS.
PMID: 31178263
Biomed Pharmacother. 2019 Aug;116:109084. doi: 10.1016/j.biopha.2019.109084. Epub 2019 Jun 06.

No abstract available.

Cite
Imran M, Rauf A, Abu-Izneid T, et al. Corrigendum to "Luteolin, a flavonoid, as an anticancer agent: A review" [Biomed. Pharmacother. 112 (2019) 108612]. Biomed Pharmacother. 2019;116:109084doi: 10.1016/j.biopha.2019.109084.
Imran, M., Rauf, A., Abu-Izneid, T., Nadeem, M., Shariati, M. A., Khan, I. A., Imran, A., Erdogan Orhan, I., Rizwan, M., Atif, M., Aslam Gondal, T., & Mubarak, M. S. (2019). Corrigendum to "Luteolin, a flavonoid, as an anticancer agent: A review" [Biomed. Pharmacother. 112 (2019) 108612]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 116109084. https://doi.org/10.1016/j.biopha.2019.109084
Imran, Muhammad, et al. "Corrigendum to "Luteolin, a flavonoid, as an anticancer agent: A review" [Biomed. Pharmacother. 112 (2019) 108612]." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 116 (2019): 109084. doi: https://doi.org/10.1016/j.biopha.2019.109084
Imran M, Rauf A, Abu-Izneid T, Nadeem M, Shariati MA, Khan IA, Imran A, Erdogan Orhan I, Rizwan M, Atif M, Aslam Gondal T, Mubarak MS. Corrigendum to "Luteolin, a flavonoid, as an anticancer agent: A review" [Biomed. Pharmacother. 112 (2019) 108612]. Biomed Pharmacother. 2019 Aug;116:109084. doi: 10.1016/j.biopha.2019.109084. Epub 2019 Jun 06. PMID: 31178263.
Copy Download .nbib Format: NLM
Corrigendum to "Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro" [Biomed. Pharmacother. 69 (2015) 402-408].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Yang F, Yu Y, Lei Q, Zeng A, Li Y, Xie Y, Ye T, Wei Y.
PMID: 31629561
Biomed Pharmacother. 2019 Dec;120:109511. doi: 10.1016/j.biopha.2019.109511. Epub 2019 Oct 16.

No abstract available.

Cite
Yang F, Yu Y, Lei Q, et al. Corrigendum to "Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro" [Biomed. Pharmacother. 69 (2015) 402-408]. Biomed Pharmacother. 2019;120:109511doi: 10.1016/j.biopha.2019.109511.
Yang, F., Yu, Y., Lei, Q., Zeng, A., Li, Y., Xie, Y., Ye, T., & Wei, Y. (2019). Corrigendum to "Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro" [Biomed. Pharmacother. 69 (2015) 402-408]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 120109511. https://doi.org/10.1016/j.biopha.2019.109511
Yang, Fangfang, et al. "Corrigendum to "Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro" [Biomed. Pharmacother. 69 (2015) 402-408]." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 120 (2019): 109511. doi: https://doi.org/10.1016/j.biopha.2019.109511
Yang F, Yu Y, Lei Q, Zeng A, Li Y, Xie Y, Ye T, Wei Y. Corrigendum to "Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro" [Biomed. Pharmacother. 69 (2015) 402-408]. Biomed Pharmacother. 2019 Dec;120:109511. doi: 10.1016/j.biopha.2019.109511. Epub 2019 Oct 16. PMID: 31629561.
Copy Download .nbib Format: NLM
Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Baghbani E, Noorolyai S, Rahmani S, Shanehbandi D, Shadbad MA, Aghebati-Maleki L, Mokhtarzadeh A, Brunetti O, Fasano R, Silvestris N, Baradaran B.
PMID: 34862113
Biomed Pharmacother. 2021 Nov 30;112370. doi: 10.1016/j.biopha.2021.112370. Epub 2021 Nov 30.

AIMS: Besides suppressing anti-tumoral immune responses, tumor-intrinsic inhibitory immune checkpoints have been implicated in tumor development. Herein, we aimed to investigate the significance of tumor-intrinsic CD73, as an inhibitory immune checkpoint, in non-small cell lung cancer (NSCLC) development and...

Cite
Baghbani E, Noorolyai S, Rahmani S, et al. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study. Biomed Pharmacother. 2021;112370doi: 10.1016/j.biopha.2021.112370.
Baghbani, E., Noorolyai, S., Rahmani, S., Shanehbandi, D., Shadbad, M. A., Aghebati-Maleki, L., Mokhtarzadeh, A., Brunetti, O., Fasano, R., Silvestris, N., & Baradaran, B. (2021). Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 112370. https://doi.org/10.1016/j.biopha.2021.112370
Baghbani, Elham, et al. "Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. (2021): 112370. doi: https://doi.org/10.1016/j.biopha.2021.112370
Baghbani E, Noorolyai S, Rahmani S, Shanehbandi D, Shadbad MA, Aghebati-Maleki L, Mokhtarzadeh A, Brunetti O, Fasano R, Silvestris N, Baradaran B. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study. Biomed Pharmacother. 2021 Nov 30;112370. doi: 10.1016/j.biopha.2021.112370. Epub 2021 Nov 30. PMID: 34862113.
Copy Download .nbib Format: NLM
Roles of mesenchymal stromal cells in the head and neck cancer microenvironment.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

de Miranda MC, Melo MIA, Cunha PDS, Gentilini J, Faria JAQA, Rodrigues MA, Gomes DA.
PMID: 34794230
Biomed Pharmacother. 2021 Dec;144:112269. doi: 10.1016/j.biopha.2021.112269. Epub 2021 Nov 05.

Head and neck cancer (HNC), a common malignancy worldwide, is associated with high morbidity and mortality rates. Squamous cell carcinoma is the most common HNC type, followed by salivary gland carcinomas, head and neck sarcomas, and lymphomas. The microenvironment...

Cite
de Miranda MC, Melo MIA, Cunha PDS, et al. Roles of mesenchymal stromal cells in the head and neck cancer microenvironment. Biomed Pharmacother. 2021;144:112269doi: 10.1016/j.biopha.2021.112269.
de Miranda, M. C., Melo, M. I. A., Cunha, P. D. S., Gentilini, J., Faria, J. A. Q. A., Rodrigues, M. A., & Gomes, D. A. (2021). Roles of mesenchymal stromal cells in the head and neck cancer microenvironment. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 144112269. https://doi.org/10.1016/j.biopha.2021.112269
de Miranda, Marcelo Coutinho, et al. "Roles of mesenchymal stromal cells in the head and neck cancer microenvironment." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 144 (2021): 112269. doi: https://doi.org/10.1016/j.biopha.2021.112269
de Miranda MC, Melo MIA, Cunha PDS, Gentilini J, Faria JAQA, Rodrigues MA, Gomes DA. Roles of mesenchymal stromal cells in the head and neck cancer microenvironment. Biomed Pharmacother. 2021 Dec;144:112269. doi: 10.1016/j.biopha.2021.112269. Epub 2021 Nov 05. PMID: 34794230; PMCID: PMC8630686.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1876 entries